-
Categories
-
Pharmaceutical Intermediates
-
Active Pharmaceutical Ingredients
-
Food Additives
- Industrial Coatings
- Agrochemicals
- Dyes and Pigments
- Surfactant
- Flavors and Fragrances
- Chemical Reagents
- Catalyst and Auxiliary
- Natural Products
- Inorganic Chemistry
-
Organic Chemistry
-
Biochemical Engineering
- Analytical Chemistry
-
Cosmetic Ingredient
- Water Treatment Chemical
-
Pharmaceutical Intermediates
Promotion
ECHEMI Mall
Wholesale
Weekly Price
Exhibition
News
-
Trade Service
This article is converted Medicine original, reproduced please indicate the source Author: Yun Introduction: Recently, scientists have identified a candidate drug that can prevent cancer cell uptake of glutamine, and can slow the growth of melanoma.
I don't know when it started, and the saying "starved to death of cancer cells" became popular.
According to reports, because cancer cells particularly like to eat sugar, if the patient strictly restricts carbohydrate intake, the cancer cells in the body will starve to death due to lack of energy.
Many studies have shown that cancer cells have long learned not to rely on glucose because they grow too fast and cannot keep up with the blood vessel supply.
When glucose is insufficient, many cancer cells change their tastes and start to eat other things, such as Glutamine.
In fact, many cancer cells prefer glutamine even if they have glucose.
Recently, researchers published a paper entitled "Identification and Characterization of IMD-0354 as a Glutamine Carrier Protein Inhibitor in Melanoma" in "Molecular Cancer Therapeutics".
The study indicated that scientists have identified a drug candidate that can block glutamine.
The uptake of amides can slow down the growth of melanoma.
A key sign of cancer is the alteration of metabolism, which is critical to the pathogenesis of cancer and treatment resistance.
Powerful glutamine metabolism is one of the cellular processes that regulates the progression and response to treatments of various tumors, including melanoma and breast cancer.
According to statistics from the American Cancer Society, in the United States, more than 7,000 people die from melanoma every year, and the number of cases continues to increase.
In the past decade, immunotherapy and personalized treatment have extended the lifespan of many patients.
However, due to the high recurrence rate of cancer, scientists are paying more and more attention to treatment strategies to prevent recurrence and increase overall survival rate.
"This is a very important study, because the rapid development of treatment resistance sometimes even within a few months has greatly hindered many targeted drugs for the treatment of melanoma.
Although immunotherapy is promising , But they are only effective for some patients, and drug resistance can also develop in this case.
" Dr.
M.
Celeste Simon said, "The study of candidate drugs has identified an exciting new therapy that can treat glutamine Amide addictive tumors are expected to extend the response time of melanoma patients to available treatments.
"Researchers know that fast-growing tumors can reprogram their metabolism to produce additional energy to survive and grow.
Tumors usually pump glutamine into cancer cells through a transporter called SLC1A5.
Now, cancer researchers are trying to find drugs that can block SLC1A5 and reduce glutamine levels.
Sanford Burnham Prebys’ team has identified a drug candidate that prevents melanoma’s ability to take glutamine.
The drug is called IMD-0354, and its role is to target SLC1A5.
The researchers first screened 7,000 compounds to find compounds that can inhibit SLC1A5.
Finally, about 20 compounds were identified, and the best IMD-0354 was selected based on its ability to prevent SLC1A5 from reaching the cell membrane.
According to a statement, they chose IMD-0354 because it prevents the transporter from penetrating the cell membrane and inhibits tumor growth in both cell culture and melanoma mice.
Although there are many targeted drugs and immunotherapies for melanoma on the market, "patients' tumors have developed resistance to the treatment, which has become a major obstacle to the successful treatment of the disease," said senior author Dr.
Ze'ev Ronai.
In the next step, Ronai's team is now working on improving the characteristics of IMD-0354 and preparing for further preclinical research.
The scientist said: "Studies have shown that targeting SLC1A5 can prevent glutamine from entering cancer cells and slow the growth of cancer cells.
Since many tumors depend on glutamine for their survival, the development of this drug will affect other types of cancer in the future.
Treatment is of great significance.
"Reference: [1] https://mct.
aacrjournals.
org/content/early/2021/02/25/1535-7163.
MCT-20-0354 [2] https://www.
fiercebiotech.
com/research/starving-tumors-to-slow-melanoma-and-pancreatic-cancer recommended reading [Nature back to back] first case! Constructed a complete human embryo model under laboratory conditions [New research] Attention cancer survivors! You have a higher risk of cardiovascular disease than normal people, so the prognosis of cancer is also very important.
[Innovative theory] Academician Fan Jia refines the important parts of spatiotemporal molecular medicine.
Spatiotemporal molecular imaging [PNAS] Milk and beef feed the "neighbors" that are not authentic ! Long-term "harassment" will eventually lead to cancer of the large intestine! Click here to read the original text
I don't know when it started, and the saying "starved to death of cancer cells" became popular.
According to reports, because cancer cells particularly like to eat sugar, if the patient strictly restricts carbohydrate intake, the cancer cells in the body will starve to death due to lack of energy.
Many studies have shown that cancer cells have long learned not to rely on glucose because they grow too fast and cannot keep up with the blood vessel supply.
When glucose is insufficient, many cancer cells change their tastes and start to eat other things, such as Glutamine.
In fact, many cancer cells prefer glutamine even if they have glucose.
Recently, researchers published a paper entitled "Identification and Characterization of IMD-0354 as a Glutamine Carrier Protein Inhibitor in Melanoma" in "Molecular Cancer Therapeutics".
The study indicated that scientists have identified a drug candidate that can block glutamine.
The uptake of amides can slow down the growth of melanoma.
A key sign of cancer is the alteration of metabolism, which is critical to the pathogenesis of cancer and treatment resistance.
Powerful glutamine metabolism is one of the cellular processes that regulates the progression and response to treatments of various tumors, including melanoma and breast cancer.
According to statistics from the American Cancer Society, in the United States, more than 7,000 people die from melanoma every year, and the number of cases continues to increase.
In the past decade, immunotherapy and personalized treatment have extended the lifespan of many patients.
However, due to the high recurrence rate of cancer, scientists are paying more and more attention to treatment strategies to prevent recurrence and increase overall survival rate.
"This is a very important study, because the rapid development of treatment resistance sometimes even within a few months has greatly hindered many targeted drugs for the treatment of melanoma.
Although immunotherapy is promising , But they are only effective for some patients, and drug resistance can also develop in this case.
" Dr.
M.
Celeste Simon said, "The study of candidate drugs has identified an exciting new therapy that can treat glutamine Amide addictive tumors are expected to extend the response time of melanoma patients to available treatments.
"Researchers know that fast-growing tumors can reprogram their metabolism to produce additional energy to survive and grow.
Tumors usually pump glutamine into cancer cells through a transporter called SLC1A5.
Now, cancer researchers are trying to find drugs that can block SLC1A5 and reduce glutamine levels.
Sanford Burnham Prebys’ team has identified a drug candidate that prevents melanoma’s ability to take glutamine.
The drug is called IMD-0354, and its role is to target SLC1A5.
The researchers first screened 7,000 compounds to find compounds that can inhibit SLC1A5.
Finally, about 20 compounds were identified, and the best IMD-0354 was selected based on its ability to prevent SLC1A5 from reaching the cell membrane.
According to a statement, they chose IMD-0354 because it prevents the transporter from penetrating the cell membrane and inhibits tumor growth in both cell culture and melanoma mice.
Although there are many targeted drugs and immunotherapies for melanoma on the market, "patients' tumors have developed resistance to the treatment, which has become a major obstacle to the successful treatment of the disease," said senior author Dr.
Ze'ev Ronai.
In the next step, Ronai's team is now working on improving the characteristics of IMD-0354 and preparing for further preclinical research.
The scientist said: "Studies have shown that targeting SLC1A5 can prevent glutamine from entering cancer cells and slow the growth of cancer cells.
Since many tumors depend on glutamine for their survival, the development of this drug will affect other types of cancer in the future.
Treatment is of great significance.
"Reference: [1] https://mct.
aacrjournals.
org/content/early/2021/02/25/1535-7163.
MCT-20-0354 [2] https://www.
fiercebiotech.
com/research/starving-tumors-to-slow-melanoma-and-pancreatic-cancer recommended reading [Nature back to back] first case! Constructed a complete human embryo model under laboratory conditions [New research] Attention cancer survivors! You have a higher risk of cardiovascular disease than normal people, so the prognosis of cancer is also very important.
[Innovative theory] Academician Fan Jia refines the important parts of spatiotemporal molecular medicine.
Spatiotemporal molecular imaging [PNAS] Milk and beef feed the "neighbors" that are not authentic ! Long-term "harassment" will eventually lead to cancer of the large intestine! Click here to read the original text
